Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 4/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | GGT1 | P19440 | 2/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.38 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27195667 | 0.85 | GRIK1 (0.42) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL1891190 | 0.85 | GRIK1 (0.42) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| SCHEMBL60233 | 0.85 | GRIK1 (0.42) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL29011629 | 0.79 | GRIK1 (0.48) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| SCHEMBL6523134 | 0.79 | SLC1A1 (0.54) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| SCHEMBL213853 | 0.79 | SLC1A1 (0.54) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| SCHEMBL28132439 | 0.79 | GRIK1 (0.41) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| SCHEMBL25491149 | 0.75 | GRIK1 (0.48) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| SCHEMBL14388352 | 0.75 | GRIK1 (0.48) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| SCHEMBL19107032 | 0.75 | GRIK1 (0.48) | GRIK1GRIK2GRM1GRM2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117802022-B | Genetic engineering bacteria for producing tetrahydropyrimidine, construction method and application thereof | 合肥中科健康生物产业技术研究院有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119161416-B | Genetically engineered bacterium for efficiently synthesizing tetrahydropyrimidine and construction method thereof | 合肥中科健康生物产业技术研究院有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119161416-A | Genetically engineered bacterium for efficiently synthesizing tetrahydropyrimidine and construction method thereof | 合肥中科健康生物产业技术研究院有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-119162214-A | Genetically engineered bacterium for efficiently synthesizing tetrahydropyrimidine and construction method thereof | 合肥中科健康生物产业技术研究院有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-117802022-A | Genetic engineering bacteria for producing tetrahydropyrimidine, construction method and application thereof | 合肥中科健康生物产业技术研究院有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-116355060-A | Homoserine transporter mutant and preparation method and application thereof | 中国科学院天津工业生物技术研究所 | 2023-06-30 | — | — | CN | disclosed |
| US-20220064692-A1 | METHOD FOR REDUCING MISINCORPORATION OF NON-CANONICAL BRANCHED-CHAIN AMINO ACIDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2022-03-03 | — | — | US | disclosed |
| EP-3899007-A1 | METHOD FOR REDUCING MISINCORPORATION OF NON-CANONICAL BRANCHED-CHAIN AMINO ACIDS | Sanofi-Aventis Deutschland GmbH (DE) | 2021-10-27 | — | — | EP | disclosed |
| CN-113557305-A | Method for reducing non-classical branched chain amino acid misincorporation | 赛诺菲-安万特德国有限公司 | 2021-10-26 | — | — | CN | disclosed |
| WO-2020126700-A1 | METHOD FOR REDUCING MISINCORPORATION OF NON-CANONICAL BRANCHED-CHAIN AMINO ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2020-06-25 | — | — | WO | disclosed |
| US-9090882-B2 | Compositions and methods for enhanced amino acid levels in plants conferred by lysine and/or threonine feedback insensitive aspartate kinase proteins | MONSANTO TECHNOLOGY LLC (US) | 2015-07-28 | — | — | US | disclosed |
| US-20110191898-A1 | Compositions and Methods for Enhanced Amino Acid Levels in Plants | MONSANTO TECHNOLOGY LLC (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010002876-A2 | COMPOSITIONS AND METHODS FOR ENHANCED AMINO ACID LEVELS IN PLANTS | MONSANTO TECHNOLOGY LLC (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20060189551-A1 | Combination therapies for fungal pathogens | DUKE UNIVERSITY (US) | 2006-08-24 | — | — | US | disclosed |
| US-5641660-A | Glutamicum threonine biosynthetic pathway | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1997-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189551-A1 | Combination therapies for fungal pathogens | FKBP2, FKBP14, FKBP1B | GRIK1 3447/4885GRIK2 3111/4885GRM1 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.